Pacira Announces FDA Approval of Exparel as a Nerve Block to Produce Regional Analgesia

PARSIPPANY, N.J., April 06, 2018 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) to broaden the use of Exparel...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news